Abbvie Biotechnology Ltd

Horizon Therapeutics USA, Inc.

Jeffrey Kent

John Lance Perez

Hartmut Kupper

Brian Lamoreaux

Arthur Kavanaugh

Edward Keystone

Gerd R Burmester

Philip Mease

Mary A Cifaldi

Daniel J Lovell

The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and azathioprine immunosuppressive therapy. Also provided are methods of reducing intolerance or enhancing immuno-tolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and azathioprine immunosuppressive therapy.

Methods for treating gout

The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF&#x3b1; inhibitor, such as a human TNF&#x3b1; antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF&#x3b1; inhibitor for treatment of rheumatoid arthritis in a subject.

Methods for determining efficacy of TNF-&#x3b1; inhibitors for treatment of rheumatoid arthritis

A new and distinctcultivar named 'Kent 33' is disclosed, characterized by an inflorescence of unique coloration and configuration. The new variety is a, normally used as an indoor ornamental plant.

plant named 'Kent 33'

A new and distinctcultivar named 'Brimstone' is disclosed, characterized by a compact plant habit, and unique bright red bracts.

plant named 'Brimstone'

A new and distinctcultivar named 'Cerise' is disclosed, characterized by a compact plant habit, and unique bright red-purple bracts.

Growing community of inventors

Vista, CA, United States of America

Jeffrey Kent